🇺🇸 FDA
Pipeline program

CAPECITABINE, CAPECITABINE, CARBOPLATIN, Datopotamab deruxtecan, ERIBULIN MESYLATE, PACLITAXEL ALBUMIN-BOUND, PACLITAXEL

D926PC00001

Phase 3 small_molecule active

Quick answer

CAPECITABINE, CAPECITABINE, CARBOPLATIN, Datopotamab deruxtecan, ERIBULIN MESYLATE, PACLITAXEL ALBUMIN-BOUND, PACLITAXEL for Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer is a Phase 3 program (small_molecule) at AstraZeneca AB with 1 ClinicalTrials.gov record(s).

Program details

Company
AstraZeneca AB
Indication
Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials